Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.46 |
| ▸ | CASP1 | P29466 | 4/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23705401 | 1.00 | TGM2 (0.52) | TGM2FOLH1CASP1SIRT2SIRT1 | |
| SCHEMBL12737519 | 0.95 | TGM2 (0.48) | TGM2FOLH1CASP1 | |
| SCHEMBL16116011 | 0.89 | SMN1; SMN2 (0.49) | TGM2FOLH1 | |
| SCHEMBL16116008 | 0.89 | SMN1; SMN2 (0.49) | TGM2FOLH1 | |
| SCHEMBL16486872 | 0.89 | MEN1 (0.52) | TGM2 | |
| SCHEMBL29773945 | 0.89 | MEN1 (0.52) | TGM2 | |
| SCHEMBL16486871 | 0.89 | MEN1 (0.52) | TGM2 | |
| SCHEMBL15631792 | 0.87 | TGM2 (0.43) | TGM2FOLH1CASP1 | |
| SCHEMBL12082261 | 0.87 | FOLH1 (0.67) | TGM2FOLH1SIRT2SIRT1 | |
| SCHEMBL25356549 | 0.84 | MEN1 (0.53) | TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240350649-A1 | TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS RELATING TO ABERRANT IMMUNE CELLS | OCTAGON THERAPEUTICS, INC. | 2024-10-24 | — | — | US | disclosed |
| EP-4096673-A1 | MODULATION OF IMMUNE CELLS | Octagon Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155277-A1 | MODULATION OF IMMUNE CELLS | OCTAGON THERAPEUTICS, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350649-A1 | TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS RELATING TO ABERRANT IMMUNE CELLS | CD74, SERPINA6, CD2BP2 | TGM2 393/4885FOLH1 752/4885CASP1 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.